Xencor Inc (XNCR) Stock AnalysisXNCRStock AnalysisXencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Xencor Inc is currently priced at $26.06, which is below the average analyst target of $29.00. However, the RSI is at 44.578, indicating a neutral momentum, and the stock has experienced a significant 5-day decline of 6.26%. The company reported a Q2 revenue of $51.22 million, which is a 17.5% year-over-year increase, showing growth potential. The main risk is the negative net income of -$128.92 million in Q1 2026, which raises concerns about profitability.

5 analysts cover XNCR: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 26.25.